<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: UK&#8217;s Multiple Sclerosis Drug Plan Fails To Deliver</title>
	<atom:link href="http://www.pharmalot.com/2009/12/uks-multiple-sclerosis-drug-plan-fails-to-deliver/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2009/12/uks-multiple-sclerosis-drug-plan-fails-to-deliver/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 21:34:27 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: pharma PR hack</title>
		<link>http://www.pharmalot.com/2009/12/uks-multiple-sclerosis-drug-plan-fails-to-deliver/#comment-448827</link>
		<dc:creator>pharma PR hack</dc:creator>
		<pubDate>Thu, 03 Dec 2009 14:09:33 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=20196#comment-448827</guid>
		<description>After reading the abstract in the British Medical Journal, it looks like the issue of cost effectiveness is in the eye of the beholder. That doesn't bode well for containing health care costs in the U.S.</description>
		<content:encoded><![CDATA[<p>After reading the abstract in the British Medical Journal, it looks like the issue of cost effectiveness is in the eye of the beholder. That doesn&#8217;t bode well for containing health care costs in the U.S.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.146 seconds -->

